Black Rock Inc. Cyma Bay Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $23 Million - $44.5 Million	1,818,243 Added 23.33%	9,610,239 $227 Million
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $3.12 Million - $5.06 Million	287,326 Added 3.83%	7,791,996 $116 Million
Q2 2023 Aug 11, 2023	BUY	$7.47 - $10.95 $36.3 Million - $53.2 Million	4,854,593 Added 183.19%	7,504,670 $82.2 Million
Q1 2023 May 12, 2023	BUY	$5.88 - $9.59 $3.73 Million - $6.09 Million	634,577 Added 31.48%	2,650,077 $23.1 Million
Q4 2022 Feb 13, 2023	BUY	$3.22 - $6.27 $228,137 - $444,229	70,850 Added 3.64%	2,015,500 $12.6 Million
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $22,766 - $34,930	-8,219 Reduced 0.42%	1,944,650 $6.81 Million
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $6.04 Million - $11.9 Million	-3,513,340 Reduced 64.27%	1,952,869 $5.76 Million
Q1 2022 May 12, 2022	BUY	$2.77 - $3.64 $393,564 - $517,174	142,081 Added 2.67%	5,466,209 $17 Million
Q4 2021 Feb 10, 2022	BUY	$3.23 - $4.6 $383,239 - $545,790	118,650 Added 2.28%	5,324,128 $18 Million
Q3 2021 Nov 09, 2021	SELL	$3.47 - $4.42 $784,886 - $999,768	-226,192 Reduced 4.16%	5,205,478 $19 Million
Q2 2021 Aug 11, 2021	BUY	$3.94 - $4.92 $21.4 Million - $26.7 Million	5,431,670 New	5,431,670 $23.7 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.